Meet our team
Chief Executive Officer
and Chairman of the Board
Raymond F. Vennare became Predictive Oncology’s CEO and Chairman of the Board on November 1, 2022. He has served on the Board of Directors since September of 2021.
Interim Chief Financial Officer
Josh Blacher, MBA is the Interim Chief Financial Officer for Predictive Oncology. As a strategic and operational CFO with more than 20 years of experience in leadership for private and Nasdaq-listed companies, Mr. Blacher specializes in the life science and biotech sectors.
Chief Business Officer
Pamela Bush, Ph.D., MBA, leads all business development, partnering and growth strategies for Predictive Oncology. As a key member of the executive team, she spearheads the company’s strategic, operational and financial planning initiatives for both existing customers and emerging new markets.
Dr. DeLucas is the Senior Vice President of Biologics for Predictive Oncology. He oversees Predictive Oncology’s solubility and stability contracts for numerous pharmaceutical/biotech companies.
SVP, Translational Medicine and Drug Discovery, Medical Director
Arlette H. Uihlein, MD, FCAP, FASCP, is Senior Vice President of Translational Medicine and Drug Discovery for Predictive Oncology and Site Leader of Helomics. She has also served as Medical Director of Helomics® Clinical and Research Labs since 2011.
Let’s discover and develop together.
We want to hear about your process challenges—and identify ways to solve them together. Complete the form to get in touch with our team of experts.